HER2 Support Group Forums - View Single Post - flu vaccination in breast cancer patients

Lani · 10-06-2006, 11:54 AM

way around it?

1: Trends Mol Med. 2006 Sep 28; [Epub ahead of print] Links
Deconstructing the molecular portrait of basal-like breast cancer.

Yehiely F,
Moyano JV,
Evans JR,
Nielsen TO,
Cryns VL.
Cell Death Regulation Laboratory, Departments of Medicine and Cell and Molecular Biology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Gene-expression profiling has revealed several molecular subtypes of breast cancer, which differ in their pathobiology and clinical outcomes. Basal-like tumors are a newly recognized subtype of breast cancer, which express genes that are characteristic of basal epithelial cells, such as the basal cytokeratins, and are associated with poor relapse-free and overall survival. However, the genetic and epigenetic alterations that are responsible for the biologically aggressive phenotype of these estrogen receptor-negative and HER2/ErbB2-negative tumors are not well understood, thereby hindering efforts to develop targeted therapies. Here, we focus on new insights into the molecular pathogenesis of basal-like breast cancer and explore how these discoveries might impact the treatment of these poor-prognosis tumors.

10-06-2006, 11:54 AM	#7
Lani Senior Member Join Date: Mar 2006 Posts: 4,780	sorry I can't post the full article for copyright reasons--perhaps Joe can suggest a way around it? 1: Trends Mol Med. 2006 Sep 28; [Epub ahead of print] Links Deconstructing the molecular portrait of basal-like breast cancer. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Cell Death Regulation Laboratory, Departments of Medicine and Cell and Molecular Biology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Gene-expression profiling has revealed several molecular subtypes of breast cancer, which differ in their pathobiology and clinical outcomes. Basal-like tumors are a newly recognized subtype of breast cancer, which express genes that are characteristic of basal epithelial cells, such as the basal cytokeratins, and are associated with poor relapse-free and overall survival. However, the genetic and epigenetic alterations that are responsible for the biologically aggressive phenotype of these estrogen receptor-negative and HER2/ErbB2-negative tumors are not well understood, thereby hindering efforts to develop targeted therapies. Here, we focus on new insights into the molecular pathogenesis of basal-like breast cancer and explore how these discoveries might impact the treatment of these poor-prognosis tumors.